Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea

18th September 2017 Uncategorised 0

Novartis, which has been trying to fix its struggling Alcon eye unit, figures that process will be easier without a floundering eye medication in the portfolio. Accordingly, it has returned the rights to Jetrea to ThromboGenics.

More: Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea
Source: fierce